1
|
Kim H, Lee J, Lim D, Kim Y, Park S, Ahn S, Kim I, Im J, Chung J, Kim J, Kim I, Yoon H, Suh C. PD-0243 Pediatric diffuse intrinsic pontine glioma treated with radiotherapy: the National multicenter study. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02798-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
2
|
Lee B, Cho J, Chang J, Kang S, Kim E, Moon J, Ahn S, Park Y, Suh C, Yoon H. PD-0246 The role of adjuvant RT in craniopharyngioma in 2021 WHO new classification of CNS tumor era. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02801-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
3
|
Yi J, Kim W, Kim S, Yoon D, Suh C, Lee WS, Yang D, Jo JC, Koh Y, Lee JO, Kim B, Lim S, Heo M, Sohn B, Choi Y, Park J, Kim H, Lee S, Oh S. 261P Clinical outcomes of early-progressed follicular lymphoma in Korea: A multicenter, retrospective analysis. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
4
|
Hohloch K, Windemuth-Kieselbach C, Zinzani PL, Cacchione R, Jurczak W, Suh C, Trümper L, Scholz CW. Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry. Ann Hematol 2020; 99:1073-1079. [PMID: 32125469 PMCID: PMC7196943 DOI: 10.1007/s00277-020-03956-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Accepted: 02/06/2020] [Indexed: 11/23/2022]
Abstract
To assess the efficacy of radioimmunotherapy (RIT) with 90yttrium-ibrutinib-tiuxetan (90Y-IT) in mantle cell lymphoma, data from 90 patients registered in the RIT Network with a median follow-up (FU) of 5.5 years after RIT were evaluated. 90Y-IT was given as first-line therapy in 45 (50%) and for relapse in 45 (50%) patients. Most patients received 90Y-IT as consolidation after chemoimmunotherapy in first line (98%) and in relapse (53%). As a first-line treatment, 30 patients (pts.) (67%) achieved CR, 10 pts. (22%) PR%. and 1 pt. (2%) PD, and for 4 pts. (9%), no response data was available. At relapse, CR was achieved in 17 pts. (38%), PR in 6 pts. (13%), SD in 2 pts. (4%), and 6 pts. (13%) had PD, while the response was not documented for 14 pts. (31%). After a median FU of 5.5 years, median PFS for all patients was 2.11 (95% CI, 1.03–2.32) years, and median OS was 4.05 (95% CI, 2.79–7.21) years. Eleven pts. (12.2%) developed second malignancy. In conclusion, this is the largest report of MCL pts. treated with 90Y-IT to date. 90Y-IT was most often used as consolidation after first- and second-line chemotherapy and may improve the results achieved using chemoimmunotherapy alone. However, the results are less encouraging compared to treatment with small molecules such as ibrutinib.
Collapse
|
5
|
Yi J, Kim W, Kim S, Yoon D, Suh C, Chang M, Yang D, Jo JC, Hyun S, Eom HS, Lee JO, Kwon J, Han S, Lee SS, Kwak JY, Kim S. Clinical outcomes of ibrutinib in patients with relapsed or refractory mantle cell lymphoma: Korean multicenter, retrospective analysis. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz446.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Jeong S, Kim S, Hong J, Park Y, Kang H, Koh Y, Lee G, Lee W, Yang D, Do Y, Kim M, Yoo K, Yun W, Yi J, Jo J, Eom H, Kwak J, Shin H, Park B, Lee J, Yi S, Kwon J, Oh S, Kim H, Sohn B, Won J, Hong D, Lee H, Suh C, Kim W. A PROSPECTIVE REGISTRY STUDY OF PEG-G-CSF PROPHYLAXIS FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (CISL 1403). Hematol Oncol 2019. [DOI: 10.1002/hon.122_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
7
|
Kim S, Jo J, Yoon D, Hong J, Do Y, Yea J, Lim S, Shin H, Lee H, Yhim H, Yi J, Choi Y, Kim M, Yang D, Lee W, Kang H, Suh C, Kim W. RANDOMIZED PHASE II STUDY OF CHOP VS. FRACTIONATED ICED IN TRANSPLANT-ELIGIBLE PATIENTS WITH PREVIOUSLY UNTREATED PERIPHERAL T-CELL LYMPHOMA: INTERIM RESULTS OF CISL1504. Hematol Oncol 2019. [DOI: 10.1002/hon.146_2631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
8
|
Lee J, Oh D, Choi B, Eom K, Lee J, Kim J, Lee S, Suh Y, Suh C. EP-1264 Patterns of care for orbital MALToma in Korea throughout 2016: a multicenter cross-sectional study. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31684-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Choi J, Kim S, Chang J, Park S, Suh C. PO-0738 Extent of resection is potent prognostic factor next to molecular subtype in low-grade glioma. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31158-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Sohn B, Lim SN, Kim J, Yoon D, Kim S, Huh J, Park SE, Yuh Y, Suh C. The β2-microgloulin is associated with the prognosis in patients with peripheral t-cell lymphoma, not otherwise specified. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy286.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Lim SN, Sohn B, Shin HJ, Suh C, Kim W, Lee W, Kim J. Combination of chemotherapy and radiation improve the prognosis of primary diffuse large B-cell lymphoma of the tonsil. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy286.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Kim E, Youm H, Kim S, Lee J, Suh C, Kim S. The effects of mouse aging on in vitro ovarian follicle development and oocyte competence. Fertil Steril 2018. [DOI: 10.1016/j.fertnstert.2018.07.541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Lim SH, Hong JY, Lim ST, Hong H, Arnoud J, Zhao W, Yoon DH, Tang T, Cho J, Park S, Ko YH, Kim SJ, Suh C, Lin T, Kim WS. Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease. Ann Oncol 2018; 28:2199-2205. [PMID: 28911074 DOI: 10.1093/annonc/mdx316] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Background Current standard treatment, including non-anthracycline-based chemotherapy and optimal combining of radiotherapy, has dramatically improved outcomes of patients with extranodal natural killer/T-cell lymphoma (ENKTL) during the last decade. This study was conducted to investigate the clinical outcome of ENKTL patients with relapsed or progressive disease after initial current standard therapy. Patients and methods We retrospectively reviewed patients diagnosed with ENKTL at six centers in four countries (China, France, Singapore, and South Korea) from 1997 to 2015 and analyzed 179 patients who had relapsed or progressed after initial current standard therapy. Results After a median follow-up of 58.6 months (range 27.9-89.2), the median second progression-free survival (PFS) was 4.1 months [95% confidence interval (CI) 3.04-5.16] and overall survival (OS) was 6.4 months (95% CI 4.36-8.51). Multivariate Cox-regression analysis revealed that elevated lactate dehydrogenase, multiple extranodal sites (≥2), and presence of B symptoms were associated with inferior OS (P < 0.05). OS and PFS were significantly different according to both prognostic index of natural killer lymphoma (PINK) and PINK-E (Epstein-Barr virus) models. Salvage chemotherapy with l-asparaginase (l-Asp)-based regimens showed a significantly better clinical benefit to response rate and PFS, although it did not lead to OS improvement. First use of l-Asp in the salvage setting and l-Asp rechallenge at least 6 months after initial treatment were the best candidates for salvage l-Asp containing chemotherapy. Conclusions Most patients with relapsed or refractory ENKTL had poor prognosis with short survival. Further studies are warranted to determine the optimal treatment of patients with relapsed or refractory ENKTL.
Collapse
|
14
|
Kwong Y, Kim S, Tse E, Oh S, Kwak J, Eom H, Do Y, Mun Y, Lee S, Shin H, Suh C, Chuang S, Lee Y, Lim S, Izutsu K, Suzuki R, Relander T, d’Amore F, Schmitz N, Jaccard A, Kim W. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. Ann Oncol 2018; 29:256-263. [DOI: 10.1093/annonc/mdx684] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
15
|
Brady J, Binkley M, Hajj C, Chelius M, Chau K, Levis M, Choi S, Suh C, Hardy S, Constine L, Krog Vistisen A, Bratman S, Reinartz G, Eich H, Oguchi M, Kirova Y, Ng A, Warbey V, Barrington S, El-Galaly T, Filippi A, Ricardi U, Yahalom J, Hoppe R, Mikhaeel N. OUTCOME OF CURATIVE RADIOTHERAPY FOR LOCALISED FOLLICULAR LYMPHOMA IN THE ERA OF 18
F-FDG PET-CT STAGING: AN INTERNATIONAL COLLABORATIVE STUDY ON BEHALF OF ILROG. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_10] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
16
|
Kang J, Hong J, Yoon D, Suh C. CLINICAL FEATURES AND SURVIVAL OUTCOMES ON LYMPHOPLASMACYTIC LYMPHOMA PATIENTS WITH NON-IGM PARAPROTEINEMIA COMPARED WITH IGM PARAPROTEINEMIA IN KOREA. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
17
|
Park B, Kim W, Suh C, Yang D, Do Y, Jo J, Park Y. A PHASE II TRIAL OF BENDAMUSTINE, CARBOPLATIN AND DEXAMETHASONE (BCD) FOR REFRACTORY OR RELAPSED PERIPHERAL T-CELL LYMPHOMA (BENCART): A CONSORTIUM FOR IMPROVING SURVIVAL OF LYMPHOMA (CISL) TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_161] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
18
|
Roh T, Kim E, Kang S, Cho J, Suh C, Kim S, Chang J. P09.45 Impact of extent of resection for long-term survival in patients with glioblastoma. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Kim H, Kim S, Chang J, Suh C, Cho J. P10.07 Prognostic factors of gliosarcoma - a single institution study. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox036.325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Kang Y, Seo S, Hong J, Yoon D, Kim S, Park J, Huh J, Lee SW, Ryu JS, Suh C. Proposal of improved prognostic index for patients with extranodal natural killer/T cell lymphoma treated with non-anthracycline based treatment. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Kim S, Shin DY, Kim J, Yoon D, Lee W, Lee H, Do Y, Kang H, Eom H, Ko Y, Lee S, Yoo H, Hong M, Suh C, Kim W. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. Ann Oncol 2016; 27:712-718. [DOI: 10.1093/annonc/mdv624] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023] Open
|
22
|
Cho Y, Kim K, Keum K, Suh C, Kim G, Kim Y. OC-0538: Tumor-related leukocytosis associated with poor radiation response and outcome in cervical cancer. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)31788-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
23
|
Lee WJ, Won KH, Won CH, Chang SE, Choi JH, Moon KC, Park CS, Huh J, Suh C, Lee MW. Secondary cutaneous lymphoma: comparative clinical features and survival outcome analysis of 106 cases according to lymphoma cell lineage. Br J Dermatol 2015; 173:134-45. [PMID: 25556641 DOI: 10.1111/bjd.13582] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/27/2014] [Indexed: 11/26/2022]
Abstract
BACKGROUND The relative frequency, clinical features and survival outcomes of secondary cutaneous lymphoma remain poorly understood. OBJECTIVES To determine the clinical characteristics and survival outcomes of secondary cutaneous lymphoma. MATERIALS AND METHODS The present retrospective cohort study included all 106 patients who presented with secondary cutaneous lymphoma. Patient medical records were reviewed to determine the clinical features, survival outcomes and prognostic factors. Survival outcomes were analysed by using the Kaplan-Meier method and comparisons between lymphoma cell lineages [T or natural killer (T-/NK)-cell vs. B-cell lymphoma] were performed using the log-rank test. RESULTS Secondary cutaneous lymphomas consisted of mature T-/NK-cell lymphomas (56%), mature B-cell lymphomas (35%), immature haematopoietic malignancies (8%) and Hodgkin lymphoma (1%). The T-/NK-cell lineage lymphoma cases were more likely to have multiple and disseminated skin lesions than the B-cell lineage lymphoma cases. The lymphoma cell lineage did not significantly influence survival outcomes. Patients who showed cutaneous involvement within 6 months of the initial diagnosis of primary disease had a poorer overall survival (OS) outcome than patients who developed cutaneous dissemination 6 or more months after the initial diagnosis (P < 0.001). Patients with disseminated skin lesions had a poorer OS than patients with localized skin lesions (P = 0.028). The two lymphoma cell lineages differed in terms of prognostic factors that influenced survival. CONCLUSIONS Skin lesion characteristics such as time point of appearance and extent affect the survival outcomes of secondary cutaneous lymphoma. Cell lineage did not influence survival outcomes but the two lineages are associated with different prognostic factors.
Collapse
|
24
|
Hong JY, Yoon DH, Suh C, Huh J, Do IG, Sohn I, Jo J, Jung SH, Hong ME, Yoon H, Ko YH, Kim SJ, Kim WS. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol 2015; 26:548-55. [PMID: 25475080 DOI: 10.1093/annonc/mdu556] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) of the elderly is defined only in adults older than 50 years. However, EBV-positive DLBCL can affect younger patients. We investigated the prevalence, clinical characteristics and survival outcomes of EBV-positive DLBCL in young adults. PATIENTS AND METHODS We analyzed patients with de novo DLBCL who were registered in the Samsung Medical Center (SMC) retrospective lymphoma cohort and prospective SMC Lymphoma Cohort Study I (ClinicalTrials.gov: NCT00822731). RESULTS A total of 571 cases were included in the analysis. The prevalence of EBV positivity was 6.7% (13/195) and 9.3% (35/376) in the young group (≤50 years) and in the elderly group (>50 years), respectively. EBV status was closely associated with unique unfavorable clinical characteristics [older age, more advanced stage, two or more sites of extranodal involvement, higher International Prognostic Index (IPI), and age-adjusted IPI risk] only in the elderly group. Poor prognostic impact of EBV positivity on overall survival was observed only in the elderly group [hazard ratio (HR) 2.86; 95% confidence interval (CI) 1.83-4.47; P < 0.001], but not in the young group (HR 1.17; 95% CI 0.35-3.89; P = 0.801). CONCLUSION A substantial proportion of EBV-positive DLBCL of the elderly can occur in young adults. EBV positivity of DLBCL in young adults was not associated with unfavorable clinical characteristics or worse outcomes. We suggest that EBV-positive DLBCL should not be confined only in the elderly and 'EBV-positive DLBCL in young adults' needs to be considered as a clinically distinct disease entity. ClinicalTrials.gov: NCT02060435.
Collapse
|
25
|
Seo S, Yoo C, Yoon D, Park C, Huh J, Suh C. Clinical Features and Outcomes of Human Immunodeficiency Virus (Hiv)-Negative Patients with Multicentric Castleman'S Disease. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu339.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|